Authors

• Severine A.R.A. Vermeire (ORCID: https://orcid.org/0000-0001-9942-3019)
• Marla C. Dubinsky (ORCID: https://orcid.org/0000-0003-4968-5795)
• Krisztina Lazin
• Peter Miles Irving (ORCID: https://orcid.org/0000-0003-0972-8148)
• Martina Goetsch
• Andrés Yarur (ORCID: https://orcid.org/0000-0003-2293-5555)
• Guibao Gu
• David T. Rubin (ORCID: https://orcid.org/0000-0001-5647-1723)
• Miguel D. Regueiro (ORCID: https://orcid.org/0000-0002-7681-8111)
• Irene Modesto
• Alexis B Dalam
• Xiang Guo (ORCID: https://orcid.org/0000-0002-7980-2246)
• Joseph Wu (ORCID: https://orcid.org/0009-0006-3464-2556)
• Laurent Peyrin-Biroulet
• Aoibhinn McDonnell (ORCID: https://orcid.org/0000-0002-2229-0382)
• Jesse Green

Institutions

• Cedars-Sinai Medical Center (US)
• Cleveland Clinic (US)
• St Thomas' Hospital (GB)
• Inserm (FR)
• Pfizer (United States) (US)
• Pfizer (United Kingdom) (GB)
• McGill University Health Centre (CA)
• University of Chicago (US)
• Pfizer (Switzerland) (CH)
• Centre Hospitalier Régional et Universitaire de Nancy (FR)
• St. Thomas Hospital (CA)
• Clinique Hartmann (FR)
• Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
• Université de Lorraine (FR)
• Icahn School of Medicine at Mount Sinai (US)
• KU Leuven (BE)

Publication Details

Journal

BMJ Open Gastroenterology

Published

2025-01-01

DOI

https://doi.org/10.1136/bmjgast-2024-001516

Citations

10

Primary Topic

Inflammatory Bowel Disease

Type

article

Field-Weighted Citation Impact

18.17

Funders

• Pfizer